MedTrace Logo

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

NCT06122389 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-01-08

No results posted yet for this study

Summary

This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.

Conditions

  • Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Interventions

DRUG

SHR2554; Chidamide analog tablets

SHR2554 + Chidamide analog tablets

DRUG

SHR2554 analog tablets; Chidamide

SHR2554 analog tablets + Chidamide

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-05
Primary Completion
2026-05-31
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06122389 on ClinicalTrials.gov